Table 2

Maternal and neonatal outcomes

Glyburide (n = 53)Metformin (n = 51)P value
Gestational age at delivery (weeks)38.1 ± 1.537.6 ± 1.20.3
Preterm delivery4 (8)6 (12)0.5
Induction/augmentation25 (47)16 (31)0.1
Caesarean section17 (32)18 (35)0.7
Mean daily glucose value under treatment (mg/dL)100.9 ± 10.4101.3 ± 9.40.9
Mean preprandial glucose value under treatment (mg/dL)88.7 ± 10.291.3 ± 8.80.2
Mean postprandial glucose value under treatment (mg/dL)115.3 ± 13.8112.6 ± 12.30.3
Maternal weight gain (kg)8.7 ± 6.68.4 ± 7.00.8
Birth weight (g)3,199 ± 4933,249 ± 4910.6
Birth weight percentile62 ± 2865 ± 270.7
Macrosomia >4,000 g1 (2)2 (4)0.6
Large-for-gestational-age neonate7 (13)10 (20)0.4
Shoulder dystocia1 (2)01
Gestational hypertension/preeclampsia5 (9)2 (4)0.4
Apgar score at 1 min <72 (4)2 (4)1
Apgar score at 5 min <71 (2)01
Cord pH*7.27 ± 0.087.27 ± 0.070.8
Head circumference (cm)33.9 ± 1.534.3 ± 1.20.3
Neonatal hypoglycemia1 (2)5 (12)**0.09
Neonatal hyperbilirubinemia19 (36)14 (27)0.4
Phototherapy10 (19)9 (18)0.9
Neonatal polycythemia3 (6)2 (4)1
Neonatal hypocalcemia2 (4)00.5
Neonatal hypomagnesemia1 (2)01
  • Data are mean ± SD or n (%).

  • *Cord pH was available for 51 and 41 neonates in the glyburide and metformin groups, respectively.

  • **Three women were switched to glyburide. Consequently, two of six newborns with hypoglycemia were exposed at birth to metformin and four to glyburide.